ID   KS6A4_HUMAN             Reviewed;         772 AA.
AC   O75676; A8K7Z8; O75585; Q53ES8;
DT   24-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   10-MAY-2017, entry version 169.
DE   RecName: Full=Ribosomal protein S6 kinase alpha-4;
DE            Short=S6K-alpha-4;
DE            EC=2.7.11.1;
DE   AltName: Full=90 kDa ribosomal protein S6 kinase 4;
DE   AltName: Full=Nuclear mitogen- and stress-activated protein kinase 2;
DE   AltName: Full=Ribosomal protein kinase B;
DE            Short=RSKB;
GN   Name=RPS6KA4; Synonyms=MSK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:CAA09009.1};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ENZYME REGULATION,
RP   INTERACTION WITH MAPK14; MAPK1 AND MAPK3, AND SUBCELLULAR LOCATION.
RC   TISSUE=Placenta {ECO:0000312|EMBL:CAA09009.1};
RX   PubMed=9792677; DOI=10.1074/jbc.273.45.29661;
RA   Pierrat B., Correia J.D.S., Mary J.L., Tomas-Zuber M., Lesslauer W.;
RT   "RSK-B, a novel ribosomal S6 kinase family member, is a CREB kinase
RT   under dominant control of p38alpha mitogen-activated protein kinase
RT   (p38alphaMAPK).";
RL   J. Biol. Chem. 273:29661-29671(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   ALA-758.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 17-727 (ISOFORM 2).
RX   PubMed=9687510; DOI=10.1093/emboj/17.15.4426;
RA   Deak M., Clifton A.D., Lucocq J.M., Alessi D.R.;
RT   "Mitogen- and stress-activated protein kinase-1 (MSK1) is directly
RT   activated by MAPK and SAPK2/p38, and may mediate activation of CREB.";
RL   EMBO J. 17:4426-4441(1998).
RN   [6]
RP   FUNCTION, INTERACTION WITH MAPK14, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF PHE-709.
RX   PubMed=11035004; DOI=10.1074/jbc.M005822200;
RA   Tomas-Zuber M., Mary J.L., Lamour F., Bur D., Lesslauer W.;
RT   "C-terminal elements control location, activation threshold, and p38
RT   docking of ribosomal S6 kinase B (RSKB).";
RL   J. Biol. Chem. 276:5892-5899(2001).
RN   [7]
RP   FUNCTION IN PHOSPHORYLATION OF HISTONE H3 AND HMGN1/HMG14.
RX   PubMed=12773393; DOI=10.1093/emboj/cdg273;
RA   Soloaga A., Thomson S., Wiggin G.R., Rampersaud N., Dyson M.H.,
RA   Hazzalin C.A., Mahadevan L.C., Arthur J.S.;
RT   "MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation
RT   of histone H3 and HMG-14.";
RL   EMBO J. 22:2788-2797(2003).
RN   [8]
RP   REVIEW ON FUNCTION.
RX   PubMed=18508628; DOI=10.2741/3122;
RA   Arthur J.S.;
RT   "MSK activation and physiological roles.";
RL   Front. Biosci. 13:5866-5879(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-347; SER-634; SER-678;
RP   THR-687 AND SER-745, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-347; THR-542 AND
RP   THR-687, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   REVIEW ON FUNCTION.
RX   PubMed=19464896; DOI=10.1016/j.tibs.2009.02.007;
RA   Vermeulen L., Vanden Berghe W., Beck I.M., De Bosscher K.,
RA   Haegeman G.;
RT   "The versatile role of MSKs in transcriptional regulation.";
RL   Trends Biochem. Sci. 34:311-318(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-347; THR-542 AND
RP   THR-687, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-678 AND SER-745, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-236 AND ALA-758.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that is required for the
CC       mitogen or stress-induced phosphorylation of the transcription
CC       factors CREB1 and ATF1 and for the regulation of the transcription
CC       factor RELA, and that contributes to gene activation by histone
CC       phosphorylation and functions in the regulation of inflammatory
CC       genes. Phosphorylates CREB1 and ATF1 in response to mitogenic or
CC       stress stimuli such as UV-C irradiation, epidermal growth factor
CC       (EGF) and anisomycin. Plays an essential role in the control of
CC       RELA transcriptional activity in response to TNF. Phosphorylates
CC       'Ser-10' of histone H3 in response to mitogenics, stress stimuli
CC       and EGF, which results in the transcriptional activation of
CC       several immediate early genes, including proto-oncogenes c-fos/FOS
CC       and c-jun/JUN. May also phosphorylate 'Ser-28' of histone H3.
CC       Mediates the mitogen- and stress-induced phosphorylation of high
CC       mobility group protein 1 (HMGN1/HMG14). In lipopolysaccharide-
CC       stimulated primary macrophages, acts downstream of the Toll-like
CC       receptor TLR4 to limit the production of pro-inflammatory
CC       cytokines. Functions probably by inducing transcription of the MAP
CC       kinase phosphatase DUSP1 and the anti-inflammatory cytokine
CC       interleukin 10 (IL10), via CREB1 and ATF1 transcription factors.
CC       {ECO:0000269|PubMed:11035004, ECO:0000269|PubMed:12773393,
CC       ECO:0000269|PubMed:9792677}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:9792677}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:9792677};
CC   -!- ENZYME REGULATION: Activated by phosphorylation at Ser-343, Thr-
CC       568 and Thr-687 by MAPK1/ERK2, MAPK3/ERK1 and MAPK14/p38-alpha,
CC       and by further autophosphorylation of Ser-196, Ser-360 and Ser-365
CC       by the activated C-terminal kinase domain. {ECO:0000250}.
CC   -!- SUBUNIT: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in
CC       quiescent cells which transiently dissociates following mitogenic
CC       stimulation. Also associates with MAPK14/p38-alpha. Activated
CC       RPS6KA4 associates with and phosphorylates the NF-kappa-B p65
CC       subunit RELA.
CC   -!- INTERACTION:
CC       Q16539:MAPK14; NbExp=4; IntAct=EBI-73933, EBI-73946;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11035004,
CC       ECO:0000269|PubMed:9792677}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O75676-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75676-2; Sequence=VSP_017733;
CC         Note=Ref.3 (BAD97281) sequence is in conflict in positions:
CC         400:QQ->Q. {ECO:0000305};
CC   -!- PTM: Ser-343 and Thr-568 phosphorylation is required for kinase
CC       activity. Ser-343 and Ser-196 are autophosphorylated by the C-
CC       terminal kinase domain, and their phosphorylation is essential for
CC       the catalytic activity of the N-terminal kinase domain.
CC       Phosphorylated at Ser-343, Thr-568 and Thr-687 by MAPK1/ERK2,
CC       MAPK3/ERK1 and MAPK14/p38-alpha. Autophosphorylated at Ser-737 and
CC       Ser-745 by the N-terminal kinase domain (By similarity).
CC       {ECO:0000250}.
CC   -!- MISCELLANEOUS: Enzyme activity requires the presence of both
CC       kinase domains. {ECO:0000250|UniProtKB:O75582}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. S6 kinase subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ010119; CAA09009.1; -; mRNA.
DR   EMBL; AK223561; BAD97281.1; -; mRNA.
DR   EMBL; AK292163; BAF84852.1; -; mRNA.
DR   EMBL; CH471076; EAW74260.1; -; Genomic_DNA.
DR   EMBL; AF074715; AAC67395.1; -; mRNA.
DR   CCDS; CCDS8073.1; -. [O75676-1]
DR   RefSeq; NP_001006945.1; NM_001006944.1. [O75676-2]
DR   RefSeq; NP_001287731.1; NM_001300802.1.
DR   RefSeq; NP_001305290.1; NM_001318361.1.
DR   RefSeq; NP_003933.1; NM_003942.2. [O75676-1]
DR   UniGene; Hs.105584; -.
DR   ProteinModelPortal; O75676; -.
DR   SMR; O75676; -.
DR   BioGrid; 114468; 15.
DR   IntAct; O75676; 5.
DR   MINT; MINT-7944429; -.
DR   STRING; 9606.ENSP00000333896; -.
DR   BindingDB; O75676; -.
DR   ChEMBL; CHEMBL3125; -.
DR   DrugBank; DB03247; Riboflavin Monophosphate.
DR   GuidetoPHARMACOLOGY; 1524; -.
DR   iPTMnet; O75676; -.
DR   PhosphoSitePlus; O75676; -.
DR   BioMuta; RPS6KA4; -.
DR   EPD; O75676; -.
DR   MaxQB; O75676; -.
DR   PaxDb; O75676; -.
DR   PeptideAtlas; O75676; -.
DR   PRIDE; O75676; -.
DR   Ensembl; ENST00000334205; ENSP00000333896; ENSG00000162302. [O75676-1]
DR   GeneID; 8986; -.
DR   KEGG; hsa:8986; -.
DR   UCSC; uc001oae.4; human. [O75676-1]
DR   CTD; 8986; -.
DR   DisGeNET; 8986; -.
DR   GeneCards; RPS6KA4; -.
DR   HGNC; HGNC:10433; RPS6KA4.
DR   HPA; CAB008649; -.
DR   HPA; HPA023225; -.
DR   MIM; 603606; gene.
DR   neXtProt; NX_O75676; -.
DR   OpenTargets; ENSG00000162302; -.
DR   PharmGKB; PA34848; -.
DR   eggNOG; KOG0598; Eukaryota.
DR   eggNOG; ENOG410XNPH; LUCA.
DR   GeneTree; ENSGT00860000133668; -.
DR   HOGENOM; HOG000233033; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; O75676; -.
DR   KO; K16510; -.
DR   OMA; YHTYLVM; -.
DR   OrthoDB; EOG091G01KO; -.
DR   PhylomeDB; O75676; -.
DR   TreeFam; TF313438; -.
DR   Reactome; R-HSA-437239; Recycling pathway of L1.
DR   SignaLink; O75676; -.
DR   SIGNOR; O75676; -.
DR   ChiTaRS; RPS6KA4; human.
DR   GeneWiki; RPS6KA4; -.
DR   GenomeRNAi; 8986; -.
DR   PRO; PR:O75676; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000162302; -.
DR   CleanEx; HS_RPS6KA4; -.
DR   ExpressionAtlas; O75676; baseline and differential.
DR   Genevisible; O75676; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004711; F:ribosomal protein S6 kinase activity; NAS:UniProtKB.
DR   GO; GO:0043987; P:histone H3-S10 phosphorylation; IMP:UniProtKB.
DR   GO; GO:0043988; P:histone H3-S28 phosphorylation; IMP:UniProtKB.
DR   GO; GO:0016572; P:histone phosphorylation; TAS:BHF-UCL.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0001818; P:negative regulation of cytokine production; TAS:UniProtKB.
DR   GO; GO:0032793; P:positive regulation of CREB transcription factor activity; TAS:UniProtKB.
DR   GO; GO:0035066; P:positive regulation of histone acetylation; IMP:BHF-UCL.
DR   GO; GO:0033129; P:positive regulation of histone phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; TAS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016239; Ribosomal_S6_kinase_II.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 2.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000606; Ribsml_S6_kin_2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 2.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome;
KW   Inflammatory response; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase;
KW   Stress response; Transferase.
FT   CHAIN         1    772       Ribosomal protein S6 kinase alpha-4.
FT                                /FTId=PRO_0000086205.
FT   DOMAIN       33    301       Protein kinase 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      302    371       AGC-kinase C-terminal.
FT   DOMAIN      411    674       Protein kinase 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      39     47       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     417    425       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      725    772       Required for nuclear targeting and
FT                                association with MAPK14.
FT   ACT_SITE    161    161       Proton acceptor. {ECO:0000250}.
FT   ACT_SITE    530    530       Proton acceptor. {ECO:0000250}.
FT   BINDING      65     65       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     440    440       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     196    196       Phosphoserine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     343    343       Phosphoserine; by MAPK1, MAPK3 and
FT                                MAPK14. {ECO:0000305}.
FT   MOD_RES     347    347       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     360    360       Phosphoserine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     365    365       Phosphoserine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     542    542       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     568    568       Phosphothreonine; by MAPK1, MAPK3 and
FT                                MAPK14. {ECO:0000250}.
FT   MOD_RES     634    634       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     678    678       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     687    687       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     737    737       Phosphoserine; by autocatalysis.
FT                                {ECO:0000305}.
FT   MOD_RES     745    745       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ     401    406       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:9687510,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_017733.
FT   VARIANT     236    236       S -> L (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation;
FT                                dbSNP:rs746466314).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040632.
FT   VARIANT     758    758       S -> A (in dbSNP:rs17857342).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_040633.
FT   MUTAGEN     709    709       F->A: Strongly elevates basal activity.
FT                                {ECO:0000269|PubMed:11035004}.
FT   CONFLICT    477    477       L -> P (in Ref. 3; BAD97281).
FT                                {ECO:0000305}.
SQ   SEQUENCE   772 AA;  85606 MW;  3606209693D0B5F3 CRC64;
     MGDEDDDESC AVELRITEAN LTGHEEKVSV ENFELLKVLG TGAYGKVFLV RKAGGHDAGK
     LYAMKVLRKA ALVQRAKTQE HTRTERSVLE LVRQAPFLVT LHYAFQTDAK LHLILDYVSG
     GEMFTHLYQR QYFKEAEVRV YGGEIVLALE HLHKLGIIYR DLKLENVLLD SEGHIVLTDF
     GLSKEFLTEE KERTFSFCGT IEYMAPEIIR SKTGHGKAVD WWSLGILLFE LLTGASPFTL
     EGERNTQAEV SRRILKCSPP FPPRIGPVAQ DLLQRLLCKD PKKRLGAGPQ GAQEVRNHPF
     FQGLDWVALA ARKIPAPFRP QIRSELDVGN FAEEFTRLEP VYSPPGSPPP GDPRIFQGYS
     FVAPSILFDH NNAVMTDGLE APGAGDRPGR AAVARSAMMQ DSPFFQQYEL DLREPALGQG
     SFSVCRRCRQ RQSGQEFAVK ILSRRLEANT QREVAALRLC QSHPNVVNLH EVHHDQLHTY
     LVLELLRGGE LLEHIRKKRH FSESEASQIL RSLVSAVSFM HEEAGVVHRD LKPENILYAD
     DTPGAPVKII DFGFARLRPQ SPGVPMQTPC FTLQYAAPEL LAQQGYDESC DLWSLGVILY
     MMLSGQVPFQ GASGQGGQSQ AAEIMCKIRE GRFSLDGEAW QGVSEEAKEL VRGLLTVDPA
     KRLKLEGLRG SSWLQDGSAR SSPPLRTPDV LESSGPAVRS GLNATFMAFN RGKREGFFLK
     SVENAPLAKR RKQKLRSATA SRRGSPAPAN PGRAPVASKG APRRANGPLP PS
//
